SRZN

Surrozen, Inc. (NASDAQ:SRZN) is a biotechnology company founded in 2015 and headquartered in South San Francisco, California. The company went public in January 2021 and focuses on discovering and developing drug candidates that selectively modulate the Wnt signaling pathway for tissue repair and regeneration. Surrozen represents a specialized approach to regenerative medicine, targeting various organ systems including the liver, intestines, retina, and other tissues through its proprietary antibody-based therapeutics.